Targets › CDH3
2 programs from 2 companies in 7 trials: 4 Phase 2, 3 Phase 1; Oncology; next expected readout Apr 2027.
Cadherins are calcium-dependent cell adhesion proteins. They preferentially interact with themselves in a homophilic manner in connecting cells; cadherins may thus contribute to the sorting of heterogeneous cell types. (UniProt, P22223)
Open in Phaseline: the race on CDH3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| University of Washington | CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine Plasmid DNA vaccine encoding multiple tumor-associated antigens (CD105/ENG, Yb-1/YBX1, SOX | ENG, YBX1, SOX2, CDH3, MDM2, CD105, YB1 | Phase 2 | Anatomic Stage IV Breast Cancer AJCC v8; Lung Non-Small Cell Carcinoma; Anatomic Stage IB Breast Cancer AJCC v8; HER2 Negative Breast Carcinoma | Apr 2027 |
| Biocity Biopharmaceutics | BC3195 anti-CDH3 antibody-drug conjugate with MMAE payload | CDH3 | Phase 1 | Advanced Cancer; Locally Advanced or Metastatic Solid Tumors | Apr 2027 |
Anatomic Stage IV Breast Cancer AJCC v8 (2) Advanced Cancer (1) Locally Advanced or Metastatic Solid Tumors (1) Lung Non-Small Cell Carcinoma (1) Anatomic Stage IB Breast Cancer AJCC v8 (1) HER2 Negative Breast Carcinoma (1)
small molecule (1), mixed (1)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.